BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with "Eye-Bulging" Tumor Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with "Ey

Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with "Eye-Bulging" Tumor

PA and VANCOUVER, British Columbia, October 1, 2024- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell"

or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is

pleased to report dramatic anti-tumor response including complete resolution of temporal lobe breast cancer metastasis in a patient treated

in the Phase 2 study of BriaCell's Bria-IMT plus an immune checkpoint inhibitor regimen. The patient demonstrated an initial

partial response at 2 months in the brain lesion with no detectable disease following 8 and 11 months of treatment.

heavily pre-treated patient who had failed 8 prior regimens including ADC therapy, previously demonstrated significant reduction of

her "Eye-Bulging" orbital tumor and continues treatment with the Bria-IMT regimen. She has completed 17 cycles

of treatment and has been on BriaCell's Phase 2 study for 12 months. Also noteworthy is a sustained drop in her tumor markers,

confirming the imaging results of marked tumor reduction.

1: Bria-IMT regimen resulted in 100% resolution of tumor in the right temporal lobe region of the brain

shown in Figure 1, the right temporal lobe lesion is no longer detectable on the images taken at 8 months and 11 months on the Bria-IMT

combination regimen. The orbital lesion has continued to shrink markedly (Figure 2). In addition, her tumor markers (blood tests that

correlate with the amount of tumor in the body) remain markedly decreased from her pre-treatment levels.

2: Bria-IMT regimen resulted in near complete resolution of breast cancer tumor in the right orbit (behind the eye)

potential therapeutic impact is unprecedented in metastatic breast cancer (MBC) in a brain metastasis setting. Our clinical findings,

demonstrating significant tumor shrinkage in metastatic brain legions, may transform the way we treat MBC patients with brain metastasis,

and offers hope to cancer patients and their families fighting this devastating disease," stated Dr. William V. Williams, BriaCell's

President and CEO. "These results support Bria-IMT as a potential new therapeutic option for MBC patients with brain metastasis.

We look forward to evaluating the brain metastasis patient subgroup in our ongoing pivotal Phase 3 study in metastatic breast cancer."

believe that the complete tumor resolution in this patient with brain metastasis, plus other cases of significant anti-cancer clinical

responses in our Phase 2 MBC patients with brain metastasis, highlight the potential application of Bria-IMT in treating similar

MBC patients," commented Dr. Giuseppe Del Priore, BriaCell's Chief Medical Officer. "The protracted time on therapy,

now one year, attests to the excellent tolerability of the Bria-IMT regimen in combination with an immune checkpoint inhibitor

which is being used in our pivotal Phase 3 study."

BriaCell Therapeutics Corp.

is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available

at https://briacell.com/.

press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,

other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements

contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"

"could," "estimate," "expect," "intend," "seek," "may," "might,"

"plan," "potential," "predict," "project," "target," "aim," "should,"

"will," "would," or the negative of these words or other similar expressions, although not all forward-looking

statements contain these words. Forward-looking statements, including those about BriaCell replicating positive data in its ongoing pivotal

Phase 3 study; BriaCell's Bria-IMT regimen bringing relief to cancer patients whose medical needs remain unmet; and the

Bria-IMT regimen becoming a therapeutic option for metastatic breast cancer patients, are based on BriaCell's current expectations

and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements

are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described

more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and

Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks

and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities

and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and

on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell

Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange)

accepts responsibility for the adequacy or accuracy of this release.

William V. Williams, MD